Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-line Trastuzumab Plus Chemoimmunotherapy for Biliary Tract Cancer (HERBOT Trial)

NCT05749900 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT05749900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05749900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-line Trastuzumab Plus Chemoimmunotherapy for Biliary Tract Cancer (HERBOT Trial)
Lead sponsor
Yonsei University
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 12, 2023
Completion date
February 28, 2027
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2 positive advanced/metastatic/nonresectable biliary tract cancer